In this study researchers are trying to find out why certain cancers stop responding to treatment with the class of drugs called PARP inhibitors.PARP inhibitors are a type of targeted cancer drug. For some women PARP inhibitors stop working and this is known as becoming resistant. Researchers want to collect samples of blood and tumour to find out …

Researchers in this study are trying to find out more about the mechanisms of action of a drug called olaparib. olaparib is a PARP inhibitor which is a targeted treatment for ovarian cancer. Researchers wish to find out why some women's ovarian cancer responds well to olaparib while other ovarian cancers don't. This information will help them to be…

The purpose of this trial is to find out how safe and effective it is to have either one or two immunotherapy drugs alongside the parp inhibitor Rucaparib. Researchers want to find out if using the different combination of drugs will prolong the time it takes for your cancer to come back compared with being treated with Rucaparib on its own. The…

Recruitment to this trial is currently paused. The researchers in this trial are looking to find how out how well the drug ceralasertib (on its own) and the combination of the drugs ceralasertib and olaparib work in rarer types of gynaecological cancers. The drugs used in this clinical trial are: Ceralasertib is a drug called an ATR inh…

The purpose of this study is to help researchers better understand how niraparib is used in the UK and how well it's tolerated by those taking it.Niraparib is a type of drug known as a PARP inhibitor. PARP inhibitors are a relatively new class of drugs known as targeted therapies. In this study the researchers wish to collect real time information …

In this trial, the researchers are trying to find out whether it's safe and effective to use a PARP inhibitor rather than standard chemotherapy in women with a BRCA gene mutation who've had two previous chemotherapy treatments. The drugs involved in this trial: Rucaparib – a targeted treatment known as a PARP inhibitor Paclitaxel – a sta…